Okedi (risperidone)
- Region
- 🇪🇺 EU
- Active substance
- risperidone
- Company
- Laboratorios Farmacéuticos Rovi, S.A.
- Status
- Authorised
- Therapeutic area
- Schizophrenia
- CHMP opinion
- Thu 16 Dec 2021
- EU approval
- Mon 14 Feb 2022
- Application
- EMEA/H/C/005406
- ATC
- N05AX08
- Official record
- www.ema.europa.eu
Indication
Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.
Regulatory milestones
No milestones recorded in the last year.
Follow Okedi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.